Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors.
Stéphanie DecaryPierre-François BerneCéline NicolazziAnne-Marie LefebvreTarik DabdoubiBéatrice CameronPierrick RivalCatherine DevaudCatherine PradesHervé BouchardAlhassan CasséChristophe HenryCéline AmaraClaire BrillacPaul FerrariLaetitia MaçonEric LacosteCecile CombeauEric BeysSouad NaimiCarlos García-EcheverríaJean-François MayauxVéronique BlancPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
On the basis of these preclinical data, the ADC SAR408701 is a promising candidate for development as a potential treatment for patients with CEACAM5-positive tumors.